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False Positive and False Negative 
FDG-PET Scans in Various 
Thoracic Diseases
Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is being used
more and more to differentiate benign from malignant focal lesions and it has
been shown to be more efficacious than conventional chest computed tomogra-
phy (CT). However, FDG is not a cancer-specific agent, and false positive findings
in benign diseases have been reported. Infectious diseases (mycobacterial, fun-
gal, bacterial infection), sarcoidosis, radiation pneumonitis and post-operative
surgical conditions have shown intense uptake on PET scan. On the other hand,
tumors with low glycolytic activity such as adenomas, bronchioloalveolar carcino-
mas, carcinoid tumors, low grade lymphomas and small sized tumors have
revealed false negative findings on PET scan. Furthermore, in diseases located
near the physiologic uptake sites (heart, bladder, kidney, and liver), FDG-PET
should be complemented with other imaging modalities to confirm results and to
minimize false negative findings. Familiarity with these false positive and negative
findings will help radiologists interpret PET scans more accurately and also will
help to determine the significance of the findings. In this review, we illustrate false
positive and negative findings of PET scan in a variety of diseases.
ifferentiation between malignant and benign pulmonary nodules is a
common problem encountered by radiologists which has provided the
impetus to explore alternative imaging techniques. Accurate diagnosis
can reduce unnecessary thoracotomies in patients with benign diseases (1). Metabolic
imaging with 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography (PET) is
being used more and more to differentiate benign from malignant focal lesions and it
has been shown to be more efficacious than conventional chest CT (2). It has a unique
ability to differentiate benign from malignant nodules, and it offers a different
approach to the diagnosis of chest diseases because it exploits fundamental biochemi-
cal differences between benign and malignant cells (2).
However, fluorodeoxyglucose (FDG) is not a cancer-specific agent, and false positive
findings in benign diseases have been reported in active inflammation or infection,
causing false-positive results (1, 2). In addition, the malignant tumors with low
metabolic activity (3) or tumors smaller than 1.0 cm in diameter (1) often show false
negative results. Furthermore, the accuracy of FDG-PET scans in detecting pulmonary
metastases in patients with cancer has not yet been established.
Awareness of the conditions and the mechanisms by which false positive and
negative results occur will help radiologists interpret PET scans more accurately and
also will help to determine the significance of the findings. In this review, potential
sources of false-positive and false-negative findings are illustrated in a variety of lung
diseases.
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DBASIC CONCEPT OF FDG-PET IMAGING
Fluorodeoxyglucose is an analog of glucose and is used
as a tracer of glucose metabolism. There are several sites of
normal physiologic accumulation of FDG (Fig. 1). It
accumulates in various normal organs which use glucose
for metabolism, including the brain, muscles, salivary
glands, myocardium, gastrointestinal tract, urinary tract,
thyroid gland, and gonadal tissues. In additional, increased
FDG uptake in brown adipose tissue in the neck has been
reported as a false positive result in 2.3 4% of patients.
Brown adipose tissue is responsible for cold-induced and
diet-induced thermogenesis. Mitochondria in brown
adipose tissue exclusively express the thermogenic protein,
and FDG uptake in hypermetabolic brown fat can occur, as
glucose transporters have been observed in brown adipose
tissue (Fig. 2) (2). 
The mechanism by which FDG uptake in tumor cells and
other pathologic conditions occurs is due to an increased
number of glucose transporter proteins and increased
intracellular hexokinase and phosphofructokinase levels,
which promote glycolysis. In the normal glycolytic
pathway, FDG behaves similarly to D-glucose in its
transport through the cell membrane and phosphorylation
by hexokinase. Once FDG is phosphorylated, structural
changes made by a hexose-phosphate bond prevent FDG
from being catabolized or transported back into the
extracellular space in substantial amounts. This process is
called “metabolic trapping,” and it makes increased uptake
and accumulation of FDG occur within abnormally
metabolizing tumor cells (2). 
Abnormal areas of FDG accumulation are detected by
comparing the uptake with background activity. In the
lungs, focal abnormalities that have a greater uptake than
the mediastinal blood pool on attenuation corrected images
are highly suggestive of malignancy. FDG PET also
provides quantitative data in the form of the standardized
uptake value (SUV) or standardized uptake ratio (SUR)
(2). The SUV is obtained by putting the circular region of
interest over the portion of the lesion with the greatest
accumulation of FDG (3). The mean SUV is obtained by
dividing the activity ( Ci/mL) in the region of interest
(ROI) by the injected dose in  Ci divided by patient weight
in grams (3). 
SUV = (average ROI activity [ Ci /mL]) / (injected dose
[ Ci] per body weight [g]) 
Increased body fat elevates the SUV, therefore, correc-
tion with lean body mass (SUVLBM) is required to avoid
erroneous comparisons that can result from changes in pre-
and post-therapy body weight in the same patient (2). The
maximum SUV is obtained by using the maximum activity
in the ROI instead of the mean activity (3).
Notwithstanding the controversial views, SUVs of 2.5 or
greater have been used as a cutoff value indicative of
malignancy (3). Gupta et al. (4) reported that FDG-PET is
superior to CT, when considering overall sensitivity,
specificity, and accuracy of PET for staging mediastinal
lymph nodes was 96, 93, and 94%, compared to 68, 65,
and 66% with CT. 
FALSE POSITIVE FINDINGS
Inflammatory cells such as neutrophil and activated
macrophages at the site of inflammation or infection show
increased FDG accumulation (5). Active granulomatous
processes, other infectious conditions and active fibrotic
lesions have also been reported to show increased FDG
accumulation and cause false-positive PET scans for
malignancy.
Tuberculoma and Tuberculous Lymphadenopathy
Tuberculoma is one of the most well-known diseases that
show intense FDG uptake (Fig. 3A). Active granulomatous
processes such as tuberculosis have been reported to
accumulate FDG (1, 2). Tuberculoma typically appears as a
fairly discrete nodule or mass (Fig. 3B) in which repeated
extensions of infection have created a central caseous
necrosis surrounded by a mantle of epithelioid cells and
collagen with peripheral inflammatory cell infiltration (1).
Activated inflammatory cells have markedly increased
glycolysis. The hexose monophosphate shunt is stimulated
by phagocytosis, with increases of 20 30 times that of
baseline values which is the cause of high FDG uptake (6).
Tuberculous lymphadenopathy can be understood in the
same manner as tuberculoma in the lung parenchyma (Fig.
4).
Elevated glucose levels can accelerate false positive
results in inflammatory conditions. It has been suggested
that inflammatory cells use more glucose under
hyperglycemia than in euglycemia, and therefore, lesions
containing such cells are more likely to be interpreted as
malignant lesions under such conditions (5).
Sarcoidosis
Sarcoidosis is a chronic multisystem disorder. It can be
characterized in affected organs by an accumulation of T
lymphocytes and mononuclear phagocytes, noncaseating
epithelioid granulomas, and derangements of the normal
tissue architecture. The etiology is unknown, but it is thought
to be caused by exaggerated cellular immune responses.
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accumulation of mononuclear inflammatory cells, mainly
CD4+ T helper 1 lymphocytes and mononuclear
phagocytes, in the affected organ. This inflammatory
process is followed by the formation of granulomas,
aggregates of macrophages and their progeny, epithelioid
cells, and multinucleated giant cells (7). Active granuloma-
tous conditions with aggregation of inflammatory cells in
sarcoidosis results in accumulation of FDG (1 3, 8), and it
has been suggested that intensity of FDG uptake may
reflect disease activity (9) (Fig. 5). 
Cryptococcosis
Cryptococcosis is an infection caused by the yeast-like
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Fig. 1. Normal distribution of FDG.
Coronal FDG-PET image shows physiologic uptake in the liver,
kidneys, intestine, and urinary bladder. Also note the minimal
uptake in the mediastinum, and bone marrow. 
Fig. 2. Normal increased FDG uptake in the shoulder area which
represents brown fat.
Fig. 3. Tuberculoma in a 53-year-old female.
A. Contrast-enhanced CT scan shows a round mass in the left lower lobe. 
B. Axial FDG-PET image shows intense uptake (arrow) in the left upper lobe suggesting a malignant condition with a maximum
standardized uptake value of 4.3. The pathologic examination reveals tuberculoma. Another lesion showing high FDG uptake
(arrowhead) is a pulmonary artery.
ABfungus Cryptococcus neoformans. This fungus reproduces
by budding and forms round, yeast-like cells. Infection
occurs by inhaling the fungus into the lungs. Pulmonary
lesions are characterized by intense granulomatous inflam-
mation (10). There are some reports which have showed
high FDG uptake causing false positive results in crypto-
coccosis (8) (Fig. 6).
Paragonimiasis
Paragonimiasis is a food-borne parasitic disease common
in south Asia, particularly in Japan, Korea and parts of
China (11). Pulmonary paragonimiasis is a disease caused
by a lung flake. Once ingested by humans, by eating
infected crabs or crayfish, the larvae excyst in the small
intestine, penetrate the intestinal wall, and enter the
peritoneal cavity. They then penetrate the diaphragm and
pleura and enter the lungs. The major target organs for the
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Fig. 5. Sarcoidosis in a 32-year-old male.
A. Axial PET-CT scans show bilateral paratracheal and hilar lymph node enlargement with high FDG uptake. 
B. Coronal section of PET shows high FDG uptake with rhamda shape (arrowheads) which is highly suggestive of sarcoidosis. A
mediastinoscopic biopsy confirms sarcoidosis.
A B
Fig. 4. Tuberculous lymphadenitis in a 56-year-old male. 
A. Axial contrast-enhanced CT scan shows right hilar lymph node enlargement (arrow). 
B. Coronal FDG-PET scan shows high uptake in the same area (arrow). 
ABlarvae are the lungs followed by the brain (12).
During the active phase of paragonimiasis, lung tissue
surrounding the parasitic cysts may contain evidence of
pneumonia, bronchitis, bronchiectasis, and fibrosis (12)
(Fig. 7A). Watanabe et al. (11) reported one case of
paragonimiasis mimicking lung cancer which showed high
FDG uptake (SUV 4.7 at one hour post-injection, and
elevation of SUV to 6.2 at two hours). Although the exact
causes of FDG accumulation have not yet been proven, we
can expect that inflammatory cells including eosinophlic
infiltration, active inflammatory responses and viable
worms cause high FDG uptake (Fig. 7B). 
Other Infectious Conditions
In variable inflammatory conditions including abscesses
(Fig. 8), glycolytic metabolism is elevated in the region of
leukocytic infiltration associated with inflammatory
processes, and consequently FDG uptake is elevated (2).
Pneumocystis infections can also cause high FDG-uptake
(Fig. 9). These conditions have not been well documented
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Fig. 6. Cryptococcosis in a 68-year-old female.
A. Contrast-enhanced CT scan shows a cavitary nodule (arrow) in the left lower lobe. 
B. Transverse section of a whole body PET image shows increased uptake (arrow) in the left lower lobe and a standardized uptake
value of 2.6. The lesion is a round mass-like lesion unlike the CT findings due to respiration artifact. 
AB
Fig. 7. Paragonimiasis in a 68-year-old male.
A. In the lung window setting, axial transverse CT scan shows linear, 
wedge shaped consolidation and small centrilobular nodules. Radiologic diagnosis
is atypical tuberculosis. 
B. Coronal section of FDG-PET image shows intense uptake in the right lower lung
zone. Bronchoscopic washing and sputum cytology reveals many parasitic eggs of
paragonimus species.
A
Bto date. However, in one report (13), patients with fever of
unknown origin presented with high FDG uptake in PET
imaging, finally proved to be infected by pneumocystis
carinii pneumoniae. Inflammatory cells increase the
expression of glucose transporters when they are activated,
and multiple cytokines and growth factors can facilitate
glucose transport without actually increasing the number
of glucose transporters (5).
Radiation Fibrosis
Inflammatory processes in radiation fibrosis is caused by
infiltration of leukocytes and macrophages and abnormal
proliferation of type II pneumocytes, radiation-induced
production of local cytokines such as platelet-derived
growth factor, tumor necrosis factor, and transforming
growth factor  in the radiation field are based on these
inflammatory morphologic changes. Consequently,
increased FDG uptake in the affected region would be
expected (Fig. 10) (14). 
Pneumoconiosis with Combined Massive Fibrosis
Pneumoconiosis is a tissue reaction to the presence of an
Chang et al.
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Fig. 8. Lung abscess in a 72-year-old male.
A. Axial contrast enhanced CT scans show a consolidation with air density in the
right upper lobe (black arrow). Multiple conglomerated mediastinal lymph node
enlargements are also noted (white arrow).
B. Coronal FDG-PET image shows high uptake (arrows) in the right upper lobe.
High uptake in the left hilar lymph node (arrowhead) is also noted. Malignancy is
suspected in PET scan. Percutaneous needle biopsy reveals a lung abscess. 
A
B
Fig. 9. Pneumocystis carinii infection in a 61-year-old female.
A. In the lung window setting of chest CT, multifocal ground-glass opacities are noted. The patient had been diagnosed with systemic
lupus erythematosus, and cytoxan and steroid pulse therapy was performed. 
B. PET-CT shows multifocal hypermetabolic lesions with an standardized uptake value of between 4.0 5.8 in both lung parenchymas.
ABaccumulation of dust in the lungs. One clinicopathologic
form of this reaction is fibrosis, while the other form
consists of aggregates of particle-laden macrophages with
minimal or no accompanying fibrosis, a reaction that is
typically seen with inert dusts such as iron, tin, and barium
(15) (Fig. 11). FDG-PET studies have revealed increased
uptake in pneumoconiosis and progressive massive fibrosis.
Some of this uptake is perhaps related to the presence of
inflammatory cells such as macrophages, as well as fibrob-
lasts (5). 
Sclerosing Hemangioma 
Sclerosing hemangioma is widely believed to arise from
type II pneumocyte and bronchial epithelial lining. It is a
benign lesion with a good prognosis. However, in some
cases it shows local invasion, multiplicity and lymph node
metastasis. The CT findings of scelrosing hemangiomas are
well defined, round or oval shaped, enhanced mass with or
without punctuate calcification. There has been only one
case report of FDG-PET findings of sclerosing
hemangioma, and in this report it shows intermediate FDG
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AB
Fig. 10. Radiation fibrosis in a 61-year-old male by radiation
therapy due to lung cancer.
A. Axial CT scan shows consolidation in the left lower lobe,
suggesting lung cancer recurrence. 
B. Axial PET image shows increased uptake in the left lower lobe
(arrow) which was mistaken for lung cancer recurrence. 
C. Microscopic image reveals severe fibrosis with inflammatory cell
accumulation.
C
Fig. 11. Progressive massive fibrosis in a 58-year-old male.
Coronal FDG-PET image shows increased uptake in right upper
lobe (arrow) and a mean standardized uptake value of 6.4.uptake (SUV= 3.0) (16) (Fig. 12).
Granulation Tissue around Tumors
Even within tumors, FDG uptake is not completely
confined to the tumor cells themselves. The newly formed
granulation tissue around the tumor and the macrophages
infiltrating the marginal areas surrounding the necrotic
area of the tumor show a high uptake of FDG. Some
authors have suggested that about 24% of the FDG
concentration in a tumor mass is derived from non-tumor
tissue (17).
FALSE NEGATIVE CONDITIONS
Tumors with low activity are well-known major causes
of false negative findings. This can be easily understood
considering the FDG PET is metabolic imaging using the
activity of lesion.
Another major cause of false negative findings for
malignancy is tumor size. It is likely a result of a loss in
measured activity as the nodule size diminishes due to the
roughly 1-cm resolution of the PET systems frequently
used (partial volume effect) (2).
Bronchioloalveolar Carcinoma (BAC)
Bronchioloalveolar carcinomas appear as areas of
ground-glass opacity, nodules, masses, or areas of ground-
glass opacity plus consolidation, on high-resolution CT
scans. On pathologic examination, bronchioloalveolar
carcinomas are well differentiated, having moderate
degrees of nuclear atypism, mild degrees of mitotic figure,
desmoplasia, and necrosis. These mild degrees of atypism,
Chang et al.
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Fig. 12. Sclerosing hemangioma in a 43-year-old female. 
A. Axial contrast-enhanced CT shows a round well demarcated, highly enhancing mass in the right lateral side of the superior vena cava
in the right upper lobe.
B. FDG-PET fusion CT image shows increased uptake in the lesion with a maximum standardized uptake value of 3.4.
AB
Fig. 13. Bronchioloalveolar carcinoma in a 75-year-old male. 
A. Contrast-enhanced CT shows a cavitary lesion in the left lower lobe (arrow). 
B. Transverse FDG-PET image of the transverse scan shows subtle uptake (arrow) in the left lower lobe with a maximum standardized
uptake value of 1.7.
ABmitosis, and desmoplasia may be the causes of lower peak
SUVs than those of other lung carcinomas. Several reports
(18) have revealed lower FDG uptake in BAC than
adenocarcinomas in the lungs. Thus, bronchioloalveolar
carcinomas can be potential causes of false negative
findings of malignancy on FDG PET scans (Fig. 13).
Furthermore, mucinous bronchioloalveolar cell carcino-
mas, which often contain abundant mucin, exhibit signifi-
cantly lower peak SUVs compared with those of squamous
cell carcinomas, adenocarcinomas, and other cell types. In
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CD
Fig. 14. Mucinous bronchioloalveolar carcinoma in a 61-year-old
female.
A, B. Axial chest CT images show a low attenuating mass in the
left upper lobe.
C. FDG-PET also shows a hypermetabolic lesion with a maximum
standardized uptake value of 3.8 in the left upper lobe.
D. Another area of ground-glass opacity is noted in the right lower
lobe.
E. FDG-PET shows no abnormal uptake in this area. Both the left
upper and right lower lobe lesions were bronchioloalveolar carcino-
mas, mucinous type. In the same patient, FDG uptake for each of
the lung lesions was different, and the amount mucin in mass may
have been the major cause of this difference. 
EChang et al.
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C
Fig. 15. Small malignant mediastinal lymph node in a 56-year-old
male.
A. Axial contrast-enhanced CT shows a nodular lesion in the right
upper lobe with a lymph node of less than 1 cm in the right
paratracheal area (arrow).
B. FDG-PET fusion CT shows no increased uptake due to the
small size of the lesion (arrow). 
C. Pathology reveals a 0.6 cm lymph node with metastatic tumor
cells.
Fig. 16. Metastatic lung nodule from mucinous carcinoma of the left breast.
A. Gadolinium-enhanded MR shows a well enhancing lobulating mass.
B. FDG-PET fusion CT shows a nodular lesion in the right lower lung without
increased FDG uptake (arrow). 
B
Asuch cases, not only histologic grade, but also the amount
of mucin component in the tumor (Fig. 14) is closely
related with FDG-uptake (18). 
Small Size Lesion 
When lesions are smaller than 1 cm, these lesions may
not show high FDG uptake in the lungs or mediastinum.
This is the result of the 1-cm resolution of PET systems
frequently used (partial volume effect) (2). Spatial resolu-
tion limitations of FDG PET have been shown to be the
causative factor of false negative PET scans (Fig. 15). 
Metastatic Lung Nodule of Extrapulmonary Neoplasm
Metastasis of tumors with a mucinous component can
result in low FDG uptake (18). The relative cellularity of
tumors is important in the detection of disease using FDG
PET. Consequently, low cellularity in these tumors caused
by the presence of mucin results in lower FDG uptake (19).
For example, lung metastasis of a mucinous carcinoma of
the breast (Fig. 16) may not show high FDG uptake. Other
metastatic tumors such as mucinous adenocarcinomas of
gastrointestinal origin can also show false negative findings
in PET scans. Also, a metastatic mass from a renal cell
carcinoma (20) (Fig. 17), and some invasive ductal and
lobular breast carcinomas (21) are well reported to result
in false negative findings. 
Chemotherapy Related Factor 
In several previous reports, it has been well documented
that FDG uptake usually decreases after chemotherapy,
and this correlates with therapeutic response. Decreased
FDG uptake after irradiation is mainly due to the reduced
number of metabolically active tumor cells. However, a
decrease of FDG PET does not always predict a good
response because FDG can differentiate metabolically
active cells from dead cells, but cannot differentiate biolog-
ically viable from metabolically active cells (22) (Fig. 18). 
Carcinoid Tumor 
Carcinoid tumors arise from the dispersed neuroen-
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C
Fig. 17. Metastasis from renal cell carcinoma in an 83-year-old
male.
A. Axial contrast-enhanced CT scans shows a mass lesion in the
right kidney suggesting renal cell carcinoma. 
B. Axial CT scan of lung window setting shows a lung nodule in the
right middle lobe (arrow).
C. A selected transverse section of whole body-PET image shows
no demonstrable uptake in the right lung. docrine system, and are classified as typical and atypical,
depending on the degree of cellular atypia. In a previous
report, the SUV in a carcinoid tumor was 1.0 2.3, which
is the result of low metabolic activity. The reason for the
low metabolic activity in the carcinoid tumor is unknown
(23).
Hyperglycemia
The biodistribution of FDG can be affected by blood
glucose levels. In situations of high blood glucose levels,
circulating blood glucose uptake in pathologic lesions
increase and this prevents FDG uptake because of the
competitive reaction (5). Therefore, a large amount of
glucose in the blood is taken up in the tumor tissue which
interferes FDG uptake in the tumor, resulting in a false
negative finding. Specifically, in type II diabetic patients
insulin may be used to manipulate glucose levels.
However, there is still no agreement as to adjusting glucose
levels in diabetic patients (2). 
CONCLUSION
Metabolic imaging with FDG-PET is beginning to play
important role in the management of oncologic diseases. In
addition, it plays a complementary role in accurate overall
evaluation of malignant diseases. However, false positive
FDG uptake or false negative PET scans are frequently
encountered. Proper interpretation and accurate character-
ization of an abnormality can be accomplished only if one
is aware of possible false positive and negative conditions. 
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